Know Cancer

forgot password

A Pharmacokinetic Study of PEG-Intron, Administered Weekly in Subjects With High-Risk Melanoma

Phase 2/Phase 3
18 Years
Not Enrolling

Thank you

Trial Information

A Pharmacokinetic Study of PEG-Intron, Administered Weekly in Subjects With High-Risk Melanoma

Inclusion Criteria:

- Subjects at least 18 years of age, of either sex, and of any race.

- Cytologically or histologically-confirmed melanoma, arising from a cutaneous or
unknown site of origin, at Stages IIB, IIC, IIIA, IIIB, IIIC according to the AJCC
2001 guidelines.

- Adequate hepatic, renal and bone marrow function within 4 weeks prior to initiation
of study treatment.

- Subjects presenting with synchronous primary and regional melanoma must have had
adequate surgical margins surrounding the primary lesion.

- Full lymphadenectomy must be performed within 90 days prior to initiation of study

- ECOG performance status of 0 or 1.

- Give informed consent according to ICH-GCP and national/local policy.

- Be able to adhere to dose and visit schedules.

- Female subjects of childbearing potential must be using a medically accepted method
of birth control prior to Screening and agree to continue its use during the study or
be surgically sterilized.

- Female subjects of childbearing potential must have a negative serum pregnancy test
at Screening.

Exclusion Criteria:

- Female subjects who are pregnant, intend to become pregnant, or are breastfeeding.

- Previous treatment with interferon alpha, chemotherapy or immunotherapy for melanoma.

- Ocular melanoma, or melanoma of the mucous membranes.

- Evidence of distant or non-regional lymph node metastases.

- In-transit melanoma, even if the lesion has been resected.

- Disease that cannot be completely surgically resected.

- Lack of recovery from recent surgery.

- Prior malignancy within the past 5 years, except surgically cured squamous cell
carcinoma of the skin, successfully resected early stage cutaneous melanoma, or
cervical carcinoma in situ.

- Severe cardiovascular disease.

- Thyroid dysfunction not responsive to therapy.

- Uncontrolled diabetes mellitus (in the opinion of the investigator).

- Active autoimmune disease.

- Active and/or uncontrolled infection.

- History of seropositivity for HIV.

- Pre-existing psychiatric condition.

- Clinical diagnosis of substance abuse of one or more of the following drugs within
the following timeframes (excluding time spent in detoxification, hospitalization or

- Alcohol, intravenous drug use, inhalational, psychotropics, narcotics, cocaine,
prescription or over-the-counter drugs: within 1 year of the Screening visit.

- Methadone, buprenorphine HCl, and/or butorphanol tartrate: within 1 year of
Screening visit, unless subject has drug screen negative for other
(non-narcotic) drugs documented in the past year and repeated negative within 2
months of Screening visit.

- Multi-drug abuse (2 or more substances in 16a and 16b): within 3 years of
Screening visit.

- Marijuana:

- If historic use is deemed excessive by the principal investigator (or
medically qualified individual), or is interfering with the subject's life,
then the subject is not eligible and should not be screened.

- If marijuana use is not deemed excessive by principal investigator and does
not interfere with life, subject must discontinue any current use of
marijuana prior to entry into study.

- Medical condition requiring chronic systemic corticosteroids.

- Known allergy to the drug substance or any of the excipients in the PEG-Intron

- Any situation or condition that, in the opinion of the investigator, may interfere
with optimal participation in the study.

- Use of any investigational drugs within 30 days of study entry.

- Participation in other clinical studies of investigational treatments.

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To establish the PK of PEG-Intron when administered at the dose and schedule used in an ongoing trial

Outcome Time Frame:

12 weeks

Safety Issue:



United States: Food and Drug Administration

Study ID:




Start Date:

February 2007

Completion Date:

July 2012

Related Keywords:

  • Melanoma
  • Melanoma